Europe — EMA
Nuvaxovid Jn.1
Matrix M, the active ingredient in Nuvaxovid Jn.1, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein presented as a dose/administration form for intramuscular use.
Request sourcing
What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv?
Matrix M, the active ingredient in Nuvaxovid Jn.1, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein presented as a dose/administration form for intramuscular use. It targets the SARS‑CoV‑2 Omicron Jn.1 variant and is intended for immunisation against COVID‑19.
GNH USA supplies Nuvaxovid Jn.1 as a licensed .
What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv used for?
Nuvaxovid Jn.1
What are the side effects of Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv?
Common
What precautions apply to Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv?
Product details
Related products
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv